Seres Therapeutics has presented compelling data at the 2026 ESCMID congress, showcasing the Phase 1b study results of its investigational live biotherapeutic, SER-155, in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). The study demonstrated that SER-155 administration leads to a significant and durable modulation of the gastrointestinal (GI) microbiome, characterized by increased abundance of SER-155 species and improved GI epithelial barrier integrity. This modulation is crucial as it can potentially reduce bacterial translocation to the bloodstream, a common risk in this patient population.

The findings underscore the therapeutic potential of SER-155 in enhancing patient outcomes by addressing microbiome disruption, a significant contributor to bloodstream infections (BSIs) in allo-HCT patients. Notably, the study reported a reduction in BSIs and systemic antibiotic exposure among SER-155-treated patients, aligning with the drug’s mechanism of action aimed at restoring gut microbiome functions and protecting the epithelial barrier. This is further supported by Dr. Jonathan Peled’s insights on the microbiome’s role in shaping clinical outcomes for immunocompromised patients, emphasizing the need for targeted interventions in this vulnerable group.

The implications of these findings are substantial for the field of microbiome-targeted therapies. SER-155’s success could catalyze a shift in research paradigms, particularly in the development of live biotherapeutics aimed at restoring microbiome health in various clinical settings. As the drug progresses toward Phase 2 trials, it may set a precedent for future microbiome-focused interventions in other conditions, including inflammatory bowel disease (IBD), thereby accelerating timelines for therapeutic development in this area.

Source: globenewswire.com